Sangamo BioSciences | SGMO - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
Alaunos Therapeutics USD 585K 84K 2025-09
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Alterity Therapeutics Limited AUD 1.45M 703.96K 2025-12
Amgen USD 1.58B 354M 2026-03
Bayer EUR 3.7B 356M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Biogen USD 554.3M 128.2M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Cipla INR 13.25B 101.8M 2025-12
Clal Biotechnology ILS 3.31M 513K 2022-12
Compugen USD 2.21M 120K 2025-12
CSL USD 1.23B 498M 2025-12
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Grifols EUR 320.45M 12.65M 2025-12
Ionis Pharmaceuticals USD 151M 21M 2026-03
J&J USD 6.03B 719M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Merck USD 2.67B 180M 2026-03
Novartis USD 3.14B 296M 2026-03
Omeros USD 11.32M 2.48M 2024-09
Pfizer USD 2.92B 1.16B 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.33B 419M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Tectonic Therapeutic USD 3.44M 1.52M 2025-12
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03